Profile
| Role | Director |
|---|---|
| Notability | 20/100 |
Board memberships
- Applied Therapeutics, Inc.
- Xeris Biopharma Holdings, Inc.
Updated Jul 16, 2026
JOHNSON JOHN has filed 5 SEC Form 4 filings across 3 companies in the last 90 days — selling. Lifetime open-market sales: $1.36M.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-23 | AXGN | Axogen, Inc. | M — Option exercise | 14.2K | $0.00 | |
| 2026-06-05 | XERS | Xeris Biopharma Holdings, Inc. | A — Grant or award | 24.2K | $0.00 | |
| 2026-06-05 | XERS | Xeris Biopharma Holdings, Inc. | S — Open-market sale | 15.0K | $6.09 | $91K |
| 2026-05-26 | VSTM | Verastem, Inc. | A — Grant or award | 36.0K | $0.00 | |
| 2026-05-08 | AXGN | Axogen, Inc. | S — Open-market sale | 11.1K | $43.26 | $478K |
| 2026-05-08 | AXGN | Axogen, Inc. | M — Option exercise | 11.1K | $7.04 | $78K |
| 2025-08-13 | XERS | Xeris Biopharma Holdings, Inc. | S — Open-market sale | 107.5K | $7.32 | $786K |
| 2024-12-20 | APLT | Applied Therapeutics, Inc. | A — Grant or award | 500.0K | $0.00 |
JOHNSON JOHN is a corporate insider — currently tracked as Director of Axogen, Inc. (AXGN). InsiderAlpha tracks every SEC Form 4 filing in real time.
5 primary Form 4 filings in the last 90 days, covering 3 companies.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($1.36M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live JOHNSON JOHN profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.